Patents Assigned to Biogen Idec
  • Publication number: 20060182740
    Abstract: The present invention provides a method for producing a concentrated antibody preparation that includes the steps of: (a) obtaining an initial antibody preparation that is an aqueous solution of antibodies and histidine or acetate buffer at a concentration in the range of from about 2 mM to about 48 mM; and (b) subjecting the antibody preparation to membrane filtration so as to remove water and buffer but not antibodies from the antibody preparation, thereby producing an antibody preparation having a higher concentration of antibodies than the initial antibody preparation. The concentrated antibody preparations produced by the method have lower viscosity and are more stable than those of other formulations. The invention further includes concentrated antibody preparations produced by the method, pharmaceutical compositions made using such preparations, and therapeutic methods in which such pharmaceutical compositions are administered to treat diseases.
    Type: Application
    Filed: June 23, 2003
    Publication date: August 17, 2006
    Applicant: Biogen Idec, Inc.
    Inventors: Tzung-Horng Yang, Michael Bacica, Michael Labarre
  • Patent number: 7087725
    Abstract: The present invention relates to Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: August 8, 2006
    Assignees: The Faculty of Medicine of the University of Geneva, Biogen Idec MA Inc.
    Inventors: Jeffrey Browning, Yves Chicheportiche
  • Patent number: 7087390
    Abstract: CAIP polypeptide, nucleic acids, ands uses thereof.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: August 8, 2006
    Assignee: Biogen Idec MA Inc.
    Inventor: Yen-Ming Hsu
  • Publication number: 20060171950
    Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
    Type: Application
    Filed: March 30, 2006
    Publication date: August 3, 2006
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna, Gary Braslawsky, Nuzhat Pathan
  • Publication number: 20060166961
    Abstract: A cell adhesion inhibitor of the general formula: R3-L-L?-R1 is disclosed. An inhibitor of the present invention interacts with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. Also disclosed are methods for preparing and using such a cell adhesion inhibitor, as well as pharmaceutical compositions containing the same.
    Type: Application
    Filed: February 27, 2006
    Publication date: July 27, 2006
    Applicant: Biogen Idec MA Inc.
    Inventors: Daniel Scott, Wen-Cherng Lee, Russell Petter, Mark Cornebise
  • Patent number: 7074406
    Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: July 11, 2006
    Assignee: Biogen IDEC Inc.
    Inventors: Amelia Black, Nabil Hanna, Eduardo A. Padlan, Roland A. Newman
  • Publication number: 20060141625
    Abstract: The disclosure provides an expression cassette and a vector comprising the cassette for expression of a polynucleotide. The expression cassette includes a promoter/enhancer, an intervening region, and a polyadenylation signal domain. Expression systems and methods of using the expression cassette and vector are also provided.
    Type: Application
    Filed: February 13, 2004
    Publication date: June 29, 2006
    Applicant: Biogen Idec MA Inc.
    Inventors: William Sisk, Holly Prentice
  • Publication number: 20060134102
    Abstract: This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other chemotherapeutic agents, as well as therapeutic methods and screening methods for identifying agents that in combination with a lymphotoxin-beta receptor agonist agent have a supra-additive effect on tumor inhibition.
    Type: Application
    Filed: June 17, 2005
    Publication date: June 22, 2006
    Applicant: Biogen Idec MA Inc.
    Inventors: Doreen LePage, Alan Gill
  • Patent number: 7060667
    Abstract: Therapeutic uses of inhibitors of the Lymphotoxin Pathway to treat tumors, specifically to treat follicular lymphomas.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: June 13, 2006
    Assignees: Biogen Idec MA, Inc., New York University
    Inventors: Jeffrey Browning, Jeanette Thorbecke, Vincent Tsiagbe
  • Publication number: 20060121028
    Abstract: Monoclonal anti-human CD20 antigen binding antibodies containing human IgG3 constant domains are provided. These antibodies possess effector functions that render them well suited for use in therapeutic methods, especially treatments wherein inhibition of B cell function or B cell number is therapeutically desirable.
    Type: Application
    Filed: January 20, 2006
    Publication date: June 8, 2006
    Applicant: Biogen Idec Inc.
    Inventor: Mitchell Reff
  • Publication number: 20060104971
    Abstract: Multivalent antibody constructs that are specific for the human lymphotoxin beta receptor, as well as their use in treating cancer and inhibiting tumor volume in a subject are disclosed.
    Type: Application
    Filed: June 17, 2005
    Publication date: May 18, 2006
    Applicant: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Veronique Bailly, Jeffrey Browning
  • Patent number: 7041290
    Abstract: Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: May 9, 2006
    Assignees: Biogen Idec MA Inc., The General Hospital Corporation
    Inventors: Veronique Bailly, Joseph Bonventre
  • Publication number: 20060089493
    Abstract: Nucleic acids and proteins that are overexpressed in colon or colorectal tumor tissues, and which are useful diagnostic and therapeutic targets.
    Type: Application
    Filed: March 28, 2003
    Publication date: April 27, 2006
    Applicant: BIOGEN IDEC INC.
    Inventors: Karen McLachlan, Dennis Gately
  • Patent number: 7034043
    Abstract: A cell adhesion inhibitor of the general formula: R3-L-L?-R1 is disclosed. An inhibitor of the present invention interacts with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. Also disclosed are methods for preparing and using such a cell adhesion inhibitor, as well as pharmaceutical compositions containing the same.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: April 25, 2006
    Assignee: Biogen Idec MA Inc.
    Inventors: Daniel Scott, Wen-Cherng Lee, Russell C. Petter, Mark Cornebise
  • Patent number: 7033589
    Abstract: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: April 25, 2006
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Publication number: 20060073147
    Abstract: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
    Type: Application
    Filed: September 21, 2005
    Publication date: April 6, 2006
    Applicant: Biogen Idec MA Inc.
    Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
  • Patent number: 7022686
    Abstract: Compounds of Formula I and II are disclosed as antagonists of subtype A1 adenosine receptors. These compounds are useful for treatment of various diseases and disorders, including systemic hypertension, renal failure, diabetes, asthma, an edematous condition, congestive heart failure, and renal dysfunction.
    Type: Grant
    Filed: May 27, 2003
    Date of Patent: April 4, 2006
    Assignee: Biogen Idec Inc.
    Inventors: Ko-Chung Lin, Chi Vu
  • Publication number: 20060058223
    Abstract: The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.
    Type: Application
    Filed: August 3, 2005
    Publication date: March 16, 2006
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Sha Mi, Jeffrey Browning
  • Publication number: 20060057162
    Abstract: Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing a microfluidized antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.
    Type: Application
    Filed: July 7, 2005
    Publication date: March 16, 2006
    Applicant: BIOGEN IDEC INC.
    Inventors: Syamal Raychaudhuri, William Rastetter, Amelia Black
  • Patent number: 7001921
    Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: February 21, 2006
    Assignee: Biogen Idec MA Inc.
    Inventors: Steven P. Adams, Ko-Chung Lin, Wen-Cherng Lee, Alfredo C. Castro, Craig N. Zimmerman, Charles E. Hammond, Yu-Sheng Liao